Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
There are few things more alarming than battling cancer. One is not having the money for its treatment. Given the recent spike in incidence of cancer and its treatment costs, this could soon be a reality than mere speculation. At present breast cancer treatment in India costs almost 6 lakhs, while i....
According to many studies, breast cancer is more common in women whose family members or blood relatives have also had breast cancer. This means that it is mostly genetic. Other factors like Radiation exposure, obesity, alcohol consumption, not having children, can all participate as risk factors fo....
Most breast lumps women feel - 8 out of 10 - aren't cancer. It's more common for them to be a cyst (a sac) or a fibroadenoma (an abnormal growth that's not cancer). Some lumps come and go during a woman's menstrual cycle. When you feel a lump in your breast, it's understandable to be concerned. B....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
كُتب بواسطة:Dr. Nitika Sharma - BDS
تمت مراجعته من قبل:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.